Dupilumab treatment of trichothiodystrophy in a child
- PMID: 38627102
- DOI: 10.1111/pde.15612
Dupilumab treatment of trichothiodystrophy in a child
Abstract
Trichothiodystrophy (TTD) is a rare congenital disorder caused by genetic mutations, leading to hair and skin abnormalities. We report successful treatment of a TTD case using dupilumab, a monoclonal antibody targeting IL-4Rα. The patient, a 7-year-old boy, exhibited significant improvement in skin and hair conditions, suggesting the potential of dupilumab as a therapeutic option for TTD. Further research is needed to elucidate its mechanism and efficacy in TTD treatment.
Keywords: atopic dermatitis; dupilumab; ichthyosis; polarized microscopy; trichothiodystrophy.
© 2024 Wiley Periodicals LLC.
References
REFERENCES
-
- Faghri S, Tamura D, Kraemer KH, Digiovanna JJ. Trichothiodystrophy: a systematic review of 112 published cases characterizes a wide spectrum of clinical manifestations. J Med Genet. 2008;45(10):609‐621.
-
- Mendelsohn BA, Beleford DT, Abu‐El‐Haija A, et al. A novel truncating variant in ring finger protein 113A (RNF113A) confirms the association of this gene with X‐linked trichothiodystrophy. Am J Med Genet A. 2020;182(3):513‐520.
-
- Zhang Y, Tian Y, Chen Q, Chen D, Zhai Z, Shu HB. TTDN1 is a Plk1‐interacting protein involved in maintenance of cell cycle integrity. Cell Mol Life Sci. 2007;64(5):632‐640.
-
- Yılmaz MA, Nasirov V, Kaya TI. Glomerular hair sign: new trichoscopic finding in a patient with trichothiodystrophy. Dermatol Ther. 2021;34(1):e14676.
-
- Morice‐Picard F, Cario‐André M, Rezvani H, Lacombe D, Sarasin A, Taïeb A. New clinico‐genetic classification of trichothiodystrophy. Am J Med Genet A. 2009;149A(9):2020‐2030.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
